Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study

• Published in: Zhong hua yi xue za zhi Vol. 87; no. 44; p. 3119
• Main Authors: DU, Zhong-Dong, Zhao, Di, DU, Jun-Bao, Lu, Shan, Yi, Jing-Mei, Hou, An-Cun, Zhou, Zhong-Shu, Ding, Guo-Fang
• Format: Journal Article
• Language: Chinese
• Published: China 27.11.2007
• Subjects: Adolescent; Child; Child, Preschool; Coronary Artery Disease - prevention & control; Female; gamma-Globulins - administration & dosage; gamma-Globulins - therapeutic use; Humans; Immunoglobulins, Intravenous - administration & dosage; Immunoglobulins, Intravenous - therapeutic use; Immunologic Factors - administration & dosage; Immunologic Factors - therapeutic use; Infant; Infusions, Intravenous; Male; Mucocutaneous Lymph Node Syndrome - drug therapy; Retrospective Studies; Treatment Outcome
• ISSN: 0376-2491

To compare the effects on Kawasaki disease (KD) of 3 different intravenous gamma globulin (IVIG) regimens and coronary complication rates in children with Kawasaki disease (KD). The clinical data of 1052 children with KD treated in 45 hospitals in Beijing from 2000 through 2004, 680 male and 372 female, aged 2 months-13.8 years, 656 (60.1%) undergoing IVIG 2 g/kg for one dose (single dose group), 292 (26.7%) undergoing 1 g.kg(-1).d(-1) for 2 days (2 d group), and 104 (9.5%) undergoing 400 - 600 mg.kg(-1).d(-1) for 4 - 5 d (4 - 5 d group) in addition of oral administration of aspirin, were analyzed retrospectively. Echocardiography was used to assess the occurrence of coronary complications 1 - 2 weeks after onset (acute stage) and 3 - 6 weeks after onset (sub-acute stage). The rate of IVIG non-responder of the 2 d group was 20.9%, significantly higher than those of the single dose group and 4 - 5 d group (9.9% and 8.7% respectively, both P < 0.01). There were no significant differences in rates of coronary co